Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study

References

• Postma DS, KoÎter GH, vd Mark TW, Reig RP, Sluiter HJ. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 1985; 87:653–657.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58:855–860.
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509–517.
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37:264–272.
   PubMed Web of Science ®Google Scholar
• Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25:2043–2048.
   PubMed Web of Science ®Google Scholar
• Agusti A, Hedner J, Marin JM, BarbÈ F, Cazzola M, Rennard S. Nighttime symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011; 20:183–194.
   PubMedGoogle Scholar
• http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed February 2013).
   Google Scholar
• Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Jr., Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47–55.
   PubMed Web of Science ®Google Scholar
• http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002211/human_med_001571.jsp&mid=WC0b01ac058001d124 (accessed March 2013).
   Google Scholar
• =Search.DrugDetails (accessed March 2013).
   Google Scholar
• Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, FalquÈs M, Caracta CF, Garcia Gil E. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012; 141:745–752.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.com 2010.
   Google Scholar
• Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005; 26:319–338.
   PubMed Web of Science ®Google Scholar
• Murray L, Houle C, Stolar M, Hsieh R, Jones PW, Monz BU, Ramachandran S, Goldman M, Sethi S, Leidy NK. Quantifying the severity of respiratory symptoms of chronic obstructive pulmonary disease (COPD): performance properties of the EXAcerbations of Chronic pulmonary disease Tool - Respiratory Symptoms (E-RS) in 3 randomized controlled trials. Am J Resp Crit Care Med 2012; 185:A1515.
   Google Scholar
• Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mˆlken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31:416–469.
   PubMed Web of Science ®Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005; 2:111–124.
   PubMedGoogle Scholar
• http://www.spiriva.com/ (accessed March 2013).
   Google Scholar
• Lasseter KC, Dilzer S, Jansat JM, Garcia Gil E, Caracta C, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther 2012; 25:193–199.
   PubMed Web of Science ®Google Scholar
• Mocarski M, Caracta C, Tourkodimitris S, Park G, Garcia Gil E, Setyawan J. Nighttime symptoms of COPD in a clinical trial population: prevalence and impact. Am J Resp Crit Care Med 2011; 183, abs A1495.
   Web of Science ®Google Scholar
• Martin RJ, Bartelson BL, Smith P, Hudgel DW, Lewis D, Pohl G, Koker P, Souhrada JF. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999; 115:1338–1345.
   PubMed Web of Science ®Google Scholar
• McNicholas WT, Calverley PM, Lee A, Edwards JC. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23:825–831.
   PubMed Web of Science ®Google Scholar
• Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148:1030–1036.
   PubMed Web of Science ®Google Scholar
• Ryan S, Doherty LS, Rock C, Nolan GM, McNicholas WT. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease. Respiration 2010; 79:475–481.
   PubMed Web of Science ®Google Scholar
• Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. Eur Respir J 2012; 40:830–836.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9:90–101.
   PubMedGoogle Scholar
• Agusti A, Jones PW, Bateman ED, Singh D, Lamarca R, de Miquel G, Caracta C, Garcia Gil E. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN. Eur Respir J 2011; 38:149.
   Google Scholar
• Kerwin E, Rennard S, Gelb AF, Rekeda L, Garcia Gil E, Caracta C. ACCORD COPD I: improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide. Poster presented at the European Respiratory Society Annual Congress, Amsterdam, The Netherlands, 24–28 September, 2011.
   Google Scholar
• http://www.exactproinitiative.com/default.php (accessed April 2013).
   Google Scholar
• Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011; 105:435–441.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Small M, Milligan G, Higgins V, Garcia Gil E, Karakurum C. Impact of patient satisfaction with their maintenance inhaler on treatment compliance and health outcomes in chronic obstructive pulmonary disease: an analysis of real-world clinical practice in Europe. Abstract presented at the British Thoracic Society Winter Meeting, London, UK, 5–7 December 2012.
   Google Scholar
• Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010; 5:401–406.
   PubMedGoogle Scholar
• Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008; 3:371–384.
   PubMedGoogle Scholar
• van der Palen J, Ginko T, Kroker A, van der Valk P, Goosens M, Padulles L, Seoane B, Rekeda L, Garcia-Gil E. Preference, satisfaction and critical errors with Genuair® and HandiHaler® in patients with COPD. Eur Respir J 2012; 40 (Suppl 56): 389s.
   Google Scholar
• Gavald‡ A, Sentellas S, AlbertÌ J, Miralpeix M, AntÛn F, Salv‡ M, Beleta J. Rapid plasma hydrolysis of aclidinium bromide, a novel long-acting anticholinergic drug. Poster presented at the European Respiratory Society Annual Congress, Berlin, Germany, 4–8 October, 2008.
   Google Scholar
• Sentellas S, Ramos I, AlbertÌ J, Salv‡ M, AntÛn F, Miralpeix M, Beleta J, Gavald‡ A. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010; 39:283–290.
   PubMed Web of Science ®Google Scholar
• Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013; 68:48–56.
   PubMed Web of Science ®Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7:CD009285.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342:d3215.
   PubMed Web of Science ®Google Scholar
• Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130:1695–1703.
   PubMed Web of Science ®Google Scholar